Medication & Safety
Return and Refund Policy: What to Check Before You Buy
A clear return and refund policy tells you a lot about a seller before anything goes wrong. Here is what to check before...
Our eligibility hub covers the adult picture. Adolescent treatment is a genuinely distinct topic, with its own trial evidence, its own specialist care requirements, and its own significant caveats, and deserves separate, careful treatment.
What the trial evidence shows
STEP TEENS, published in the New England Journal of Medicine in 2022, enrolled 201 adolescents aged 12 to 17 with obesity or overweight and at least one weight-related health condition. Participants received once-weekly semaglutide or placebo for 68 weeks under close medical supervision.
The results were substantial: a mean BMI reduction of 16.1 percent in the semaglutide group versus 0.6 percent with placebo, with most adolescents receiving semaglutide losing 5 percent or more of body weight.
Why this is a genuinely different situation from adult treatment
Growth and development are still occurring. Adolescence involves ongoing physical, hormonal and psychological development, which means treatment decisions carry considerations that simply do not apply to a fully grown adult.
Eligibility criteria in the trial were strict: obesity or overweight specifically combined with a weight-related comorbidity, not general dissatisfaction with weight, and participants underwent extensive screening before enrolment.
Specialist paediatric obesity management is required, not a scaled-down adult protocol. This involves paediatric endocrinology or specialist adolescent medicine expertise, family involvement, and psychological support alongside the medication itself.
The psychological dimension is significant. Adolescence is a period of particular vulnerability around body image, and any weight management approach needs careful psychological framing to avoid unintended harm to a young person's relationship with their body and food.
What responsible adolescent treatment requires
A specialist, not a general prescription. This is a paediatric endocrinology or specialist adolescent obesity medicine decision, involving assessment well beyond BMI alone.
Family involvement throughout, since adolescent treatment decisions are not made in isolation from the family context and support system.
Ongoing monitoring for growth and development, distinct from the monitoring an adult would receive, given the active developmental period involved.
Addressing underlying causes and behaviours, not medication as a standalone intervention, consistent with how the trial itself embedded semaglutide within lifestyle intervention rather than using it alone.
The Pakistan-specific reality
No GLP-1 medication is registered in Pakistan for any age group, and this is particularly consequential for adolescents, where the specialist infrastructure, paediatric endocrinology with obesity medicine expertise, that responsible treatment requires is itself limited. Pursuing unregulated, informally imported medication for an adolescent, without the specialist oversight the trial evidence was generated under, carries meaningfully higher risk than the equivalent decision for an adult.
What this means practically for a parent
If you are concerned about a teenager's weight, the appropriate first step is a paediatrician or specialist adolescent medicine consultation, addressing the full picture, nutrition, activity, psychological wellbeing, and underlying medical causes, rather than seeking medication as a first response, particularly given the current absence of a regulated pathway in Pakistan.
Where this leaves the decision
METASLIM™ and the METASLIM™ program are formulated and positioned for adult use, and this article does not endorse or recommend its use for adolescents. Any weight management decision for a teenager should go through appropriate paediatric specialist care rather than an adult-oriented program or product.
For adult family members considering their own weight management, review the program structure separately from any decision regarding a teenager in your household.
The summary
The STEP TEENS trial found semaglutide produced substantial BMI reduction in adolescents 12 to 17 with obesity, under strict trial conditions and close specialist supervision.
Adolescent treatment requires specialist paediatric obesity management, family involvement and developmental monitoring, not a scaled-down adult approach.
No GLP-1 medication is registered in Pakistan for any age group, making the specialist-supervised pathway the trial evidence describes currently unavailable here.
Concerns about a teenager's weight are best addressed through paediatric specialist consultation first, rather than seeking medication independently.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.